Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Standard Biotools (LAB) Other Operating Expenses (2016 - 2026)

Standard Biotools has reported Other Operating Expenses over the past 16 years, most recently at $13.3 million for Q4 2025.

  • Quarterly Other Operating Expenses rose 138.96% to $13.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, up 108.72% year-over-year, with the annual reading at $14.8 million for FY2025, 108.76% up from the prior year.
  • Other Operating Expenses was $13.3 million for Q4 2025 at Standard Biotools, up from $43000.0 in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $14.8 million in Q3 2021 and troughed at -$57.7 million in Q2 2024.
  • The 5-year median for Other Operating Expenses is $32000.0 (2022), against an average of -$15.1 million.
  • Year-over-year, Other Operating Expenses tumbled 196309.52% in 2023 and then surged 138.96% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at $14.8 million in 2021, then plummeted by 60.4% to $5.9 million in 2022, then crashed by 1040.94% to -$55.3 million in 2023, then surged by 38.41% to -$34.0 million in 2024, then surged by 138.96% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Operating Expenses are $13.3 million (Q4 2025), $43000.0 (Q3 2025), and $271000.0 (Q2 2025).